Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Gene transfer with herpes simplex vectors.

R H Lachmann¹, S Efstathiou

¹Department of Medicine, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK. rhl20@cus.cam.ac.uk

Current Opinion in Molecular Therapeutics

|March 16, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

White matter integrity correlates with cognition and disease severity in Fabry disease.

Brain : a journal of neurology·2020

Same author

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

European journal of neurology·2017

Same author

Childhood Pompe disease: clinical spectrum and genotype in 31 patients.

Orphanet journal of rare diseases·2016

Same author

Analyses of herpes simplex virus type 1 latency and reactivation at the single cell level using fluorescent reporter mice.

The Journal of general virology·2015

Same author

Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.

Journal of inherited metabolic disease·2014

Same author

A practical approach to diagnosing adult onset leukodystrophies.

Journal of neurology, neurosurgery, and psychiatry·2013

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

This review discusses progress in developing safe herpes simplex virus (HSV) gene delivery vectors. It covers strategies for effective transgene expression in cells and animal models.

Area of Science:

Virology
Gene Therapy
Molecular Biology

Background:

Developing safe viral gene delivery vectors requires addressing replication-disabled construction and transgene expression.
Herpes simplex virus (HSV) offers potential as a gene delivery vector but requires careful engineering.

Purpose of the Study:

To review advancements in herpes simplex virus (HSV)-based gene delivery vectors.
To discuss strategies for achieving effective transgene expression in target cells.
To summarize experimental findings from HSV vector applications in vitro and in vivo.

Main Methods:

Review of existing literature on HSV vector development.
Analysis of strategies for creating replication-disabled HSV vectors.
Evaluation of methods for controlling transgene expression from HSV vectors.

Related Experiment Videos

Main Results:

Significant progress has been made in constructing replication-disabled HSV vectors for enhanced safety.
Various strategies have been explored to achieve regulated and appropriate transgene expression.
HSV vectors have demonstrated efficacy in gene delivery within tissue culture and animal models.

Conclusions:

Herpes simplex virus (HSV) vectors are promising tools for gene therapy, with ongoing development focused on safety and efficacy.
Further research is needed to optimize transgene expression and delivery efficiency for clinical applications.
HSV-based gene delivery holds potential for treating various diseases through targeted genetic modification.